

# Postoperative Nutrition and Nutritional Complications in Patients with Bariatric Surgery: An Update

Bariatrik Cerrahi Geçiren Hastalarda Postoperatif Beslenme ve Beslenme ile İlgili Komplikasyonlar: Güncelleme

<sup>®</sup>Havva SEZER, <sup>®</sup>Dilek YAZICI

Department of Section of Endocrinology and Metabolism, Koç University Faculy of Medicine, İstanbul, TURKEY

#### Abstract

Bariatric surgery is the most effective therapeutic option for long-term weight loss among patients with morbid obesity. Nutrition after bariatric surgery is a very specialized condition. The most severe complications that can develop after bariatric surgery are nutritional deficiencies and the diseases related to them, such as anemia and osteoporosis. Screening associated with nutritional deficiencies should be performed preoperatively to optimize the postoperative outcomes and the nutritional status of patients. Bariatric surgeries such as Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD-DS) reduce nutrient absorption. Moreover, bariatric surgery can exacerbate preexisting nutritional deficiencies. Patients who have undergone bariatric surgery should be followed up for common micronutrient deficiencies and protein-calorie malnutrition. There are gaps in the postoperative follow-up of these patients. This review aimed to focus on the postoperative nutritional strategies and nutritional complications in patients who have undergone bariatric surgery.

Keywords: Bariatric surgery; nutrition; nutrient deficiency

# Özet

Bariatrik cerrahi ciddi obezitesi olan hastalar arasında uzun süreli kilo kaybında en etkili tedavi yöntemidir. Bariatrik cerrahi sonrası beslenme cok özel bir konudur. Bariatrik cerrahi sonrası gelişebilecek en ciddi komplikasyonlar beşlenme yetersizlikleri ve bunlarla ilişkili anemi ve osteoporoz gibi hastalıklardır. Postoperatif sonuçları ve hastaların beslenme durumunu optimize etmek için beslenme yetersizlikleri ile ilişkili tarama preoperatif dönemde başlatılmalıdır. Roux-en-Y gastrik bypass (RYGB) ve biliopankreatik diversiyon-duodenal switch (BPD-DS) gibi ameliyatlar besin emilimini azaltır. Ayrıca, bariatrik cerrahi daha önceden var olan beslenme yetersizliklerini siddetlendirebilir. Bariatrik cerrahi geçiren hastalar yaygın mikro besin eksiklikleri ve proteinkalori yetersizliği açısından takip edilmelidir. Bu hastaların postoperatif takiplerinde boşluklar vardır. Bu derleme makale, bariatrik cerrahi geçirmiş hastalarda postoperatif beslenme stratejilerine ve beslenme ile ilgili komplikasyonlara odaklanmayı amaçladı.

#### Anahtar kelimeler: Bariatrik cerrahi; beslenme; besin eksikliği

## Introduction

Therapeutic options for obesity have trended toward bariatric surgeries in recent decades. Bariatric surgery involves different procedures that can be restrictive, malabsorptive, or a combination of both. Malabsorptive procedures lead to weight loss by intestinal segment bypass that reduces food absorption. Restrictive procedures lead to weight loss by restricting food intake (1). Restrictive procedures include laparoscopic sleeve gastrectomy (LSG), laparoscopic adjustable gastric banding (LAGB), and vertical band gastroplasty. Malabsorptive procedures in-

Address for Correspondence: Havva SEZER, Department of Section of Endocrinology and Metabolism, Koç University Faculy of Medicine, İstanbul, TURKEY Phone: :90 21246787006 E-mail: hasezer@kuh.ku.edu.tr

Peer review under responsibility of Turkish Journal of Endocrinology and Metabolism.

Publication and hosting by Turkiye Klinikleri.

This is an open access article under the CC BY-NC-SA license (https://creativecommons.org/licenses/by-nc-sa/4.0/)

clude jejunoileal bypass and biliopancreatic diversion (BPD). The combined procedures include Roux-en-Y gastric bypass (RYBG) and biliopancreatic diversion with duodenal switch (BPD-DS) (1).

Bariatric surgery aims to help patients achieve maximum sustainable weight loss and maintain a proper nutritional balance (2). Bariatric surgeries can exacerbate malnutrition and micronutrient losses, which are risk factors for obesity. Thus, nutrient deficiencies should be screened before the surgery, and the detected deficiencies should be replenished. This is essential because the patients that apply for weight loss surgery (WLS) have at least one mineral or vitamin deficiency (3). Compared with restrictive malabsorptive procedures, procedures cause nutritional deficiencies more frequently (4).

# **Postoperative Dietary Strategy**

Nutritional intake following bariatric surgery consists of the following five stages: stage 1 (first 1–3 days) is clear fluid diet, stage 2 (1-2 weeks) is fluid diet, stage 3 (3-4 weeks) is pureed diet, stage 4 (5-8 weeks) is soft diet, and stage 5 (from week 9 on) is normal diet (5).

Within the first 24 h of the surgery, clear fluids containing low carbohydrates should be given to the patients. On the first postoperative day, 30-60 g of non-carbonated and caffeine-free fluids every hour, totaling up to 750-1000 mL/day (d), should be given. The volume of fluids should be increased up to 1500-2000 mL/d from the second day to maintain adequate hydration (2). Fluids should not be consumed with solid foods. It is advised to keep a 30 min interval between the solid foods and fluids consumption to prevent gastrointestinal symptoms (2).

During the first 3 weeks, patients should drink only liquids with enough protein (in the form of powder), and enough hydration should be provided. In stage 3, pureed foods can be given. Pureed foods can be described to the patients as foods that can be swallowed without chewing (2). In stage 4, the patients can be given soft foods that do not require excess chewing (2). In stage 5, most patients can start eating some solid foods. They can eat all types of solid foods as per tolerance (2). Daily calorie intake is 400 kcal/d in the first postoperative week, which progresses to 600-800 kcal/d by the third and fourth week. From the fifth week, patients are advised to consume 1200-1500 kcal/d. Most patients can consume approximately 1500-1800 kcal/d, 6 months after surgery (2).

Patients who have undergone bariatric surgery should not consume concentrated sweets to reduce caloric intake and dumping symptoms (2). Two main dishes and three snacks are recommended to these patients. Sufficient protein intake is very crucial. Protein can be provided by mixing protein powder with fluids during the first three weeks. Carbohydrates should constitute 50% of the total calories intake. Consumption of complex carbohydrates such as fruit, vegetables, and grains is recommended (50 g/d in the early postoperative day and up to 130 g/d as diet intake increases in the following days) (2).

Crushed or liquid form of medications should be used and long-acting drugs should be avoided to maximize absorption during the early postoperative period (2).

Patients should be advised to eat slowly by chewing thoroughly. They should stop eating once they feel satiated. If the food is ingested guickly or the guantity of food is more than the stomach pouch capacity, the patient can experience vomiting or gastric distress. Therefore, patients should decide their food intake. In the early postoperative phase, patients utilize calories (energy) mainly from their fat deposits. They require nutritional supplementation and good hydration from outside. After their weight is stabilized, patients get most of their calories from the nutrients in their diet. Their nutrient requirements are similar to those of people without bariatric surgery (2).

Before surgery, the patient's basal vitamin and mineral levels should be evaluated. In the follow-up, these levels need to be evaluated at regular time intervals. If any deficiencies are observed, then they should be replenished. Patients that undergo LSG, RYGB, and BPD-DS should be prescribed 2 adult multivitamin supplements containing minerals (iron, folic acid, and thiamine), 1200-1500 mg of elemental calcium supplements (calcium citrate), minimum of 3,000 IU of vitamin D supplements (titrated to 25hydroxyvitamin D levels >30 ng/mL), and vitamin B12 supplements (sublingual, oral, subcutaneous, or intramuscular formulations) to keep their nutrient and micronutrient levels within normal limits (2).

In patients that undergo LAGB, an adult multivitamin supplement containing minerals (folate, thiamine, and iron) should be taken every day. Also, elemental calcium supplement (calcium citrate) up to 1200-1500 mg and a minimum of 3,000 IU of vitamin D (titrated to 25-hydroxyvitamin D levels >30 ng/mL) are required (6-8). Multivitamin and mineral supplement therapies should be continued lifelong.

Nutritional support should be given to patients with WLS that are at high nutritional risk (Nutrition Risk Score  $\geq$ 3) (Table 1 and Table 2) (9). Life-treatening complications that requiring admission to the intensive care unit may develop in patients following bariatric surgery. The complications that are likely to see early (<30 d) are anastomotic leaks, gastrogastric fistulas, gastrointestinal haemorrhages, and perforations, on the other hand bowel obstructions, anastomotic strictures, and band erosions occur after the first 30 d. Oral intake is avoided to manage of gastrointestinal complications until the complication has resolved (10-14). Parenteral nutrition (PN) should be given to the patients that cannot use their gastrointestinal tract for at least 3-7 days with critical illness or 5-7 days with noncritical illness (2). PN therapy is also recommended for patients with severe malnutrition and hypoalbuminemia who are not responsive to oral or enteral protein supplementation (15, 16). There is no consensus for the nutritional requirements for obese patients requiring nutritional support following bariatric surgey. PN treatment should contain hypoenergic high protein nutrients for patients with WLS (2).

## **Nutrient Deficiencies**

Protein and micronutrients deficiencies are mainly seen in patients with bariatric surgery. Nutrient deficiencies are due to insufficient calorie intake, differences in the digestive anatomy, malabsorption, and bacterial overgrowth in the small intestines (17).

The type of surgery determines the nutritional deficiencies. As the procedure be-

| Tabl | e 1. Nutritional risk screening (9).                  |
|------|---|
| Init | tial screening<br>Yes No                              |
| 1    | Is the BMI below 20.5?                                |
| 2    | Has the patient lost weight in the last three months? |
| 3    | Did the patient have a reduced                        |
|      | dietary intake in the last week?                      |
| 4    | Is the patient severely ill?                          |
| Yes  | : If the answer is "Yes" to any of the questions,     |
| the  | screening in Table 2 is performed.                    |
| No:  | If the answer is "No" to all of the questions,        |
| the  | patient is rescreened at weekly intervals.            |
|      |   |

BMI: Body mass index.

comes more complicated, the chances of malnutrition increase. Nutrient deficiencies are common after malabsorptive surgeries like RYGB and BPD-DS. Malnutrition is observed after LSG to a lesser extent (18-22). In RYBG and BPD-DS, the duodenum and some parts of the small intestine are removed. These regions are responsible for the absorption of folate, vitamin B12, vitamin D, and minerals like iron and calcium (23). BPD-DS is the least performed bariatric surgery. Protein malnutrition, diarrhea, and fat-soluble vitamins deficiencies are observed after this procedure. Nutritional deficiencies after restrictive procedures are related to the diet and eating habits of the patients. The decrease in nutrient intake, poor food choices, food intolerance, excessive vomiting, and insufficient portion size may cause nutritional deficiencies. Excessive vomiting can lead to acute thiamine deficiency. Also, decreased food intake and especially meat can lead to nutrideficiencies (24).tional Bacterial overgrowth in the small intestine can develop after bariatric surgery, which can increase the risk of micronutrient deficiencies (25).

# **Protein Deficiency**

Protein digestion begins in the stomach with the release of hydrochloric acid. The inactive pepsinogen is converted to active pepsin in the acidic environment of the stomach (26). Dietary protein intake decreases after

| tus Severity of disease   | Absent Score 0 Normal nutritional status | last three months or food intake Mild Score 1 Hip fracture, chronic patients (cirrhosis, COPD, chronic irmal requirement in the previous week. | last two months, or BMI is between Moderate Score 2 Major abdominal surgery, stroke, pneumonia, hematologic eral status or food intake is 25-60% malignancy in the previous week. | last one month (>15% in 3 months)     Severe Score 3     Head injury, bone marrow transplantation, intensive care<br>patients or food intake is 0-25%       in the previous week. | Score = Total score | nutritional care plan should be initiated                        |
|---------------------------|--|--|---|---|---------------------|--|
| Impaired nutritional stat | Normal nutritional status                | Weight loss is >5% in the la<br>is below 50-75% of the nor   | Weight loss is >5% in the la<br>18.5-20.5 + impaired gene<br>of the normal requirement i  | Weight loss is >5% in the la<br>or BMI <18.5 + impaired ge<br>of the normal requirement i   | +                   | d 1 to total score above<br>tt is nutritionally at risk, and a n |
| Final screening           | Absent Score 0                           | Mild Score 1   | Moderate Score 2  | Severe Score 3  | Score               | Age if ≥70 years: ad<br>Score ≥3: the patien                     |

BMI: Body mass index, COPD: Chronic obstructive pulmonary disease, APACHE: Acute physiology and chronic health evaluation

bariatric surgery. Gastric acid and pepsinogen secretion are significantly reduced in the stomach. The secretion of pancreatic enzymes is reduced. All these reasons alter normal protein digestion in the duodenum. Postoperative alteration in the taste and olfactory perception can also decrease protein intake (26). Adequate protein intake is very important to avoid malnutrition. Protein intake should be calculated based on the age, sex, and weight of the patient (2). Excess hair loss can be the first symptom of protein malnutrition. Moreover, poor wound healing, sarcopenia, edema, anemia, and hypoalbuminemia can also be observed. Protein replenishment should begin from the second postoperative day. Protein should constitute 10% of the total daily calories intake. The daily protein requirement will be at least 60 g/d (adequate intake is up to 1.5 g/kg of ideal body weight (IBW) per day) and should be calculated for each patient by the dietician (maximum protein intake can be up to 2.1 g/kg IBW per day) (27). As per the guidelines (2,5), a minimum of 120 g/d protein should be given to patients with BPD, and a minimum of 60 g/d protein should be given to patients with RYGB or LSG (2). The recommended daily intake of protein after bariatric surgery may be up to 0.8-1 g/kg IBW per day in patients with stage 3-5 chronic kidney disease without dialysis. For patients on dialysis, the minimum protein requirement is 1.2 g/kg IBW per day. For patients that underwent kidney transplantation, protein intake is less restricted (≥1.1 g/kg IBW per day) and dependent on kidney function (28).

The reduction of protein intake leads to loss of muscle mass in the first month after bariatric surgery. It has been reported that during the first year after LSG and RYGB, the majority of patients could not intake the advised protein intake of a minimum of 60 g daily (29). Additionally, Verger et al. reported that nearly one-third of the patients suffered from mild protein deficiency (29). Protein deficiency was also observed in the patients at the first and third months of postoperative LAGB (30). A study by Giusti et al. reported inadequate protein intake until three years of RYGB (31). Protein supplements are generally prescribed to replenish protein levels. Schollenberg et al. observed that daily protein supplements (30-35 g of protein powder) positively influence both body weight loss and body composition within the six months follow-up (32). 0.5 g whey protein supplement/kg IBW helps to achieve desired body weight and fat loss after RYGB (33). Oral protein supplements should be consumed for six months after LSG or RYGB (32).

## **Micronutrients and Their Deficiencies**

#### **Calcium-Vitamin D**

Calcium is absorbed maximum in the duodenum and proximal jejunum, but it is absorbed passively throughout the gastrointestinal tract. Surgeries that decreased gastric acidity like RYGB, LSG, BPD-DS have also increased the risk of calcium malabsorption. Calcium is absorbed in the presence of vitamin D. Vitamin D is absorbed maximum in the jejunum, and ileum and these regions are bypassed in RYGB and BPD-DS (34). In patients with obesity, vitamin D deficiency and secondary hyperparathyroidism are seen even before bariatric surgery. Patients that undergo BPD-DS are especially at increased risk of vitamin D deficiency due to fat malabsorption (35). Secondary hyperparathyroidism due to vitamin D deficiency is seen after surgery as well (36, 37).

Calcium citrate, vitamin D (ergocalciferol [vitamin D2] or cholecalciferol supplements [vitamin D3]) should be prescribed to patients that underwent RYGB, BPD, or BPD-DS, at a concentration that does not cause hypercalciuria. Calcium citrate is absorbed better when the gastric pouch has less acidity. Calcium carbonate, which is more easily available as supplements, does not get absorbed well in the less acidic environment. Thus, after LSG, when acid-producing cells are present to some extent, calcium carbonate can be prescribed. In addition, 40-50% of calcium citrate is absorbed, while less than 10% of calcium carbonate is absorbed. Hence, the deposition of excess calcium carbonate can lead to the formation of kidney stones. In case of severe vitamin D malabsorption, 50,000 IU oral doses of vitamin D2 or D3 1-3 times a week should be prescribed. Calcitriol may be added in resistant cases at doses of 0.25-4  $\mu$ g daily. Hypophosphatemia can also be observed due to vitamin D deficiency. In the case of hypophosphatemia (1.5-2.5 mg/dL), phosphate supplements should be given orally (2).

#### Iron

Patients with obesity generally develop iron deficiency. Insufficient iron intake, higher requirement, and low-grade chronic inflammation inhibit the absorption of iron and can lead to the development of iron deficiency in patients with obesity (38). After consumption, dietary iron (heme and non-heme forms) is oxidized to ferric (3+) state by the acid environment for solubility. In the duodenum, iron is reduced to a ferrous (2+) state by duodenal ferro-reductase for absorption (39). Iron is absorbed in the duodenum and proximal jejunum. After bariatric surgery, decreased secretion of hydrochloric acid, use of proton-pump inhibitor (PPI), faster gastric emptying, and reduced surface area may lower iron absorption. Low iron levels in the diet, decreased oral intake, and intolerance to iron-rich foods (red meat) can also contribute to iron deficiency (24). The iron level should be evaluated after all bariatric surgeries. It has been observed that the prevalence of iron deficiency ranges is between 1 to 54% after LSG (24). Routine evaluation of iron levels for all patients is advised, especially after LSG, RYGB, or BPD-DS (40) within 3 months of post-operation, then every 3-6 months until 12 months, and then once a year (2). Additionally, before bariatric surgery, 15% of patients with obesity have anemia, of which 47% had anemia due to iron deficiency (41). Therefore, the iron level should be evaluated during the preoperative period as well. The most common symptom of iron defi-

ciency after bariatric surgery is hair loss (42). Fatigue, decreased work performance, impaired learning ability, glossitis, vertical ridges on nails, and palpitation can also be observed (43). Iron supplements should be prescribed as oral ferrous sulfate, fumarate, or gluconate. To replenish serum iron levels, 45-60 mg is recommended daily via multivitamins in patients with post-RYGB, LSG, or BPD-DS (2). Oral iron supplements cause significant gastrointestinal side effects, which can have an additive role in iron deficiency. In patients with WLS with iron deficiency, oral supplements should he increased to obtain 150-200 mg elemental iron daily (43). Vitamin C should be also be prescribed to increase the absorption of iron. Patients that are unable to tolerate oral iron supplements and patients with severe malabsorption can be administered intravenous iron infusions along with ferric gluconate or sucrose (44,45). The resolution of the coexisting inflammatory state may decrease ferritin level in patients who underwent bariatric surgery (46).

#### Vitamin B12 (Cobalamin)

Vitamin B12 deficiency is due to the depletion of parietal cells that secrete gastric acid and due to the deficiency of intrinsic factor (47). Vitamin B12 deficiency can also be associated with a reduced intake of vitamin B12-rich foods because of intolerance (48). PPI intake can contribute to vitamin B12 deficiency (49). The symptoms of vitamin B 12 deficiency include paleness with slightly icteric eyes and skin, glossitis, fatigue, paresthesia, numbness in extremities, vertigo, and palpitation (43). Deficiency of vitamin B12 can be observed after RYBG or LSG. It is observed in one-third or more patients in the postoperative period (50,51). A meta-analysis study reported that LSG leads to a less postoperative risk of vitamin B12 deficiency compared with RYGB (52).

Vitamin B12 deficiency is a permanent situation that requires lifelong medication (23). Vitamin B12 deposits in the body are present for 18 months; thus, symptoms of vitamin B12 deficiency are seen late in the postoperative period. Vitamin B12 levels should be evaluated before and yearly after LSG and RYBG. To maintain a normal serum level of vitamin B 12, can be prescribed 350-500  $\mu$ g daily, sublingually or orally, provided that the absorption is adequate (2). Doses up to 1000  $\mu$ g may need to be taken daily. Intranasal vitamin B12 500  $\mu$ g/week can also be prescribed. If the patient is unable to maintain normal vitamin B12 levels by oral supplements, vitamin B12 can also be given intramuscularly or subcutaneously,  $1000 \mu g$ /month or  $1000-3000 \mu g$  every 6 to 12 months (2,5).

#### Vitamin B9 (Folate)

Because folic acid can be absorbed throughout the small intestine, particularly in the jejunum, vitamin B9 deficiency is rare compared with vitamin B12. As folate is a hydrophilic vitamin, it is not stored in the body; therefore, deficiencies may occur in cases of inadequate oral ingestion (17). The most important dietary source of folic acid is green leafy vegetables. Folic acid deficiency can be observed along with vitamin B12 deficiency because vitamin B12 plays a role in converting folate to its active form (methyltetrahydrofolic acid→tetrahydrofolic acid). The most common causes of megaloblastic anemia are vitamin B9 and vitamin B12 deficiencies. Common symptoms of folate deficiency include fatigue, muscle weakness, pale skin, the feeling of pins, tingling or burning in the extremities, and memory problems (43). Folic acid deficiency is rare after restrictive surgery but common after malabsorptive surgery (2). Evaluation of Vitamin B9 level is recommended for all patients (2). Different supplement dosages are mentioned in the literature. Cappocia et al. observed adequate folate levels in patients that were prescribed standard oral folate supplements after LSG (53). This data suggests that folic acid absorption from the distal intestine is protected after LSG (54). However, Hakeam et al. reported that patients might need more than the daily recommended dose to keep folic acid levels within the normal range (55). Folic acid may be provided as 400-800 µg/d folate in multivitamins or as 800-1000 µg/d folate in prenatal supplements to decrease the risk of fetal neural tube defects (56).

#### Vitamin B1 (Thiamine)

Thiamine is a cofactor for several metabolic pathways in glycolysis to neurotransmitter synthesis. It is mainly absorbed in the duodenum and proximal jejunum. The deficiency of thiamine impairs oxidative metabolism that leads to oxidative stress, inflammation, and neurodegeneration (57,58). Thiamine deficiency is increased,

especially after RYBG and BPD-DS. It may be observed in patients with progressive emesis and/or severely restricted oral intake of food after three weeks of bariatric surgery (59). After only 20 days of insufficient oral intake, thiamine reserves in the body are depleted. Thiamine deficiency occurs faster than other vitamin deficiencies. Thiamine deficiency was reported along with intestinal flora changes after RYBG (60). Since thiamine is transported by albumin, its levels will be reduced with concomitant hypoalbuminemia. Wernicke's encephalopathy occurs because of thiamine deficiency, which is characterized by oculomotor dysfunction, confusion, and walking ataxia (58,59). Patients with rapid weight loss, progressive weight loss, parenteral feeding, excessive alcohol consumption, neuropathy, encephalopathy, or cardiac failure should be screened for thiamine deficiency. Routine screening after bariatric surgery is not recommended (2).

Thiamine can be provided along with multivitamins. To normalize serum thiamine levels, at least 12 mg should be administered to the patients. Preferably a 50-100 mg of thiamine with multivitamins may be given to some patients daily to obtain adequate thiamine (2). In patients with severe thiamine deficiency, 500 mg/d thiamine should be given intravenously for 3-5 days. Thereafter, 250 mg/d thiamine should be given intravenously for 3-5 days or until the symptoms subside, and then 100 mg/d thiamine should be given orally to maintain thiamine levels. Mild deficiency could be treated with intravenous administration of thiamine, 100 mg/d, for 7-14 days. In case of recurrent thiamine deficiency or deficiency that cannot be fixed, antibiotics for bacterial overgrowth can be given. Antibiotics such as metronidazole, amoxicillin, or rifaximin can be given orally for 7-10 days every two months (60). Probiotic therapy can be planned for patients with antibiotic resistance (1).

#### Selenium

Selenium is absorbed in the duodenum and proximal jejunum (61). The occurrence of selenium deficiency after RYBG and BPD-DS is observed to be 14% and 22%, respec-

tively (62). Striated muscle dysfunction, cardiomyopathy, mood changes, disorders of the immune system, progressive persistent diarrhea, decreased pigmentation, metabolic bone disease, and unexplained anemia may be observed in patients with selenium deficiency. The interval between the therapeutic supplementation of selenium is very less; toxic doses are very close to the therapeutic doses. Selenium supplementation is recommended at a dose of 2  $\mu$ g/kg of IBW/d.

#### Zinc

Zinc plays an important role in DNA synthesis, wound healing, and protein synthesis. Zinc is absorbed in the duodenum and proximal jejunum. It is also involved in fat absorption. Zinc deficiency can be observed after malabsorptive procedures (63). It was observed in 11% patients in the postoperative 2-3 years period after BPD and BPD-DS (62) and 6-40% patients after RYBG (63). It was also reported after LSG (3). The risk factors that can contribute to zinc deficiency include reduction in gastric HCl that limits zinc absorption and insufficient intake of dietary zinc (64). Zinc deficiency should be screened for patients with hair loss, distorted taste perception, pica, delayed wound healing, skin lesions, immune deficiency, and in males with hypogonadism and erectile dysfunction. Screening should be done at least once a year for post-RYGB and post-BPD-DS patients regardless of the symptoms (2). Multivitamins containing 8-22 mg/d zinc will be enough to prevent zinc deficiency (2).

#### Copper

Copper is essential for the synthesis of erythrocyte and leucocyte and the normal functioning of the central nervous system (essential for neurotransmitter synthesis) (61). It is absorbed in the stomach and proximal jejunum (65). Copper deficiency has been reported after RYBG and BPD-DS (66). In a retrospective screening of 136 patients that underwent RYBG, the prevalence of copper deficiency was 10% (67). A lower rate of copper deficiency is observed after LSG (3). Copper deficiency is more evident with iron supplementation (2). Routine screening for copper is not recommended but is considered in the cases of anemia, neutropenia, ataxia, myeloneuropathy, and difficulties in wound healing. Supplementation with 1-2 mg/d of elemental copper may be started for all patients post-WLS (2). In case of serious copper deficiency, intravenous copper (3-4 mg/d) may be given for six days, followed by oral administration of copper sulfate or gluconate (3-8 mg/d) until the copper level is normal and symptoms disappear. Although hematological conditions improve after two months of copper supplementation, neurological problems require supplementation for a longer period. In the small intestine, zinc competes with copper for absorption. Because zinc supplementation can lead to copper deficiency, 1 mg of copper should be given for every 8-15 mg of elemental zinc supplementation (2).

## **Fat-Soluble Vitamins**

Fat-soluble vitamins are primarily absorbed in the jejunum and ileum (35). Deficiencies are observed, especially in patients with RYBG (23) and BDS-DS (68,69). Routine screening is not recommended for vitamin E and K deficiencies. Vitamin A deficiency may be screened in patients with malabsorptive procedures. Bariatric patients with vitamin A deficiency should be screened for concurrent iron and/or copper deficiencies because these deficiencies can prevent the recovery of vitamin A deficiency (6). Screening is advised for these patients within the first postoperative year regardless of the symptoms (70,71). To prevent deficiencies, 5,000-10,000 IU vitamin A, 15 mg vitamin E, and 90-120 µg vitamin K (300 µ for post-BPD-DS) are recommended daily (2).

A summary of micronutrient deficiencies, nutrient supplementation, and replenishment after WLS is given in Table 3.

## **Screening for Micronutrient Deficiencies**

Guidelines (2,5) recommend the micronutrient screenings should be conducted at 1, 3, to 6 and 12 months postoperatively (2). Thereafter, screening depends on the type of surgical procedures and known micronutrients deficiencies (2).

Screenings should include complete blood count, electrolytes, glucose, iron, iron-binding capacity, transferrin saturation, ferritin, vitamin B12, aminotransferases, alkaline phosphatase, bilirubin, albumin, lipid profile, 25-OH vitamin D, parathyroid hormone, thiamine, folate, zinc, and copper. If any other deficiency is observed, follow-up for the same should be performed (21).

## Other Complications Related to Nutrition After Bariatric Surgery

#### Anemia

The etiology of anemia should be determined even in the absence of blood loss during the surgery. The main causes of anemia are iron, folic acid, and vitamin B12 deficiencies. In the absence of these deficiencies, protein, copper, selenium, and zinc deficiencies should be screened (72).

#### Osteoporosis

Vitamin D deficiency is commonly seen in patients with obesity. A large amount of adipose tissue in patients with obesity serves as a reservoir for vitamin D, which can lead to vitamin D deficiency (73). Hepatic synthesis of 25-OH vitamin D also decreases in patients with obesity (73). Secretions of the visceral fat increase the level of proinflammatory cytokines, which then increases vitamin D resorption in the bones (74). Obesity may increase the risk of fall-related injuries and extremity fractures because of the impairment in mobility and loss of muscle strength (75).

There is a strong association between the extent of weight loss and the amount of bone loss after bariatric surgery (76). The detrimental effects of bariatric surgery on bones are mainly due to calcium and vitamin D deficiencies, which can cause secondary hyperparathyroidism. The bone fragility increases after bariatric surgery due to skeletal changes. Loss of bone mineral density has been reported in patients that undergo RYGB and LSG (77). A significant increase in the carboxy-terminal telopeptide of collagen type I (CTX) levels has been reported after five years of LSG (78). However, bone turnover markers increased to a lesser extent after LSG compared with RYGB (78). In a study where 94% of the patients underwent bypass surgery, the risk for any type of fracture increased 2.3-fold. After 10+ years post-surgery, the reported risk

| Vitamine B1 (thiamine)       High-risk groups       At least 12 mg once cally       100 mg 23 times colosities on a plant time form of the poly of the matrix patients on a plant time form of the poly of the matrix patients or a plant time form of the poly of the matrix plant on a plant time form of the poly of the matrix plant on a plant time form of the poly of the poly of the poly of the plant of | Micronutrient                       | Monitoring               | Supplementation to prevent deficiency                 | Replenishment for patients with deficiency          |
|---|-------------------------------------|--------------------------|---|---|
| Preferably 56-100 mg 1-2 times orally in the form of<br>multivitamin supplements for at-risk pattents       10 500 mg/d 3-5 day<br>days or unit symptom         Vitamin B1_2 (cobalamin)       Pest-LSG, post-RVGb,<br>or post-BPD-DS       -350-500 ug oral/sublingual daily<br>or post-BPD-DS       -1000 ug daily to ach<br>days or unit symptom         Foldate       - All patients       -1000 ug daily to ach<br>days or unit symptom       -1000 ug daily to ach<br>daily to ach<br>days or unit symptom         Foldate       - All patients       - All patients       -1000 ug oral daily<br>or notable       -1000 ug daily to ach<br>daily to mothly<br>daily to ach<br>daily to mothly       -1000 ug daily to ach<br>daily to mothly         Foldate       - All patients       - All patients       -1000 ug daily to mothly<br>daily to mothly the form data<br>daily to male weat       -1000 ug daily to ach<br>daily to male weat         Foldation       - All patients       - All patients       -1000 ug daily for males that       -1000 ug daily daily<br>daily threates         Foldation       - All patients       - All patients       -1.000 ug daily daily<br>daily threates       -1.000 ug daily daily<br>daily threates       -1.000 ug daily daily<br>daily daily         Vitamin D       - All patients      1.000 ug daily daily       -1.000 ug daily daily       -1.000 ug daily daily         Vitamin D       - All patients       -1.000 ug daily for males that       -1.000 ug daily       -1.000 ug daily         Vitamin D      1.000 ug  | Vitamin B1 (thiamine)               | -High-risk groups        | -At least 12 mg once orally                           | -100 mg 2-3 times orally daily until symptoms       |
| Wtamin B12 (cobalamin)     -Best-LSC, post-RYCB, and sulfy an anticination or any to maintain nor or any to maintain nor or any to maintain nor or any to maintain nor or post-BPD-DS     -1,000 ug and vality anticination or any to maintain nor or any to maintain nor or post-BPD-DS       Vtamin B12 (cobalamin)     -Pest-LSC, post-RYCB, and solver and any or post-BPD-DS     -1,000 ug and vality in women of the even and solver and                  |                                     |                          | -Preferably 50-100 mg 1-2 times orally in the form of | resolve   |
| Vtamin B12 (cobalamin)       Post-LSC, post-KYGb, cordingual daily to main symptom       days or until symptom         Vtamin B12 (cobalamin)       Post-LSC, post-KYGb, cordingual daily       350-500 ug oral/subingual daily       1,000 ug daily to ach         Toron       -All patients       -300-500 ug oral daily       1,000 ug daily to ach       1,000 ug daily to ach         Toron       -All patients       -400-500 ug oral daily       1,000 ug oral daily to ach       1,000 ug oral daily to ach         Toron       -All patients       -All patients       -400-500 ug oral daily for momen of the resume dosages       1,000 ug oral daily to ach       1,000 ug oral daily to ach         Toron       -All patients       -All patients       -All patients       -400-500 ug oral daily for momen of the resume dosages       150, or KYBC       -1,000 ug oral daily to ach         Toron       -All patients       -All patients       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily to ach       -1,000 ug oral daily to ach         Toron       -All patients       -All patients       -All patients       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily for momen of the resume dosages       -1,000 ug oral daily for momen of the resume dosages <t< td=""><td></td><td></td><td>multivitamin supplements for at-risk patients</td><td>-IV 500 mg/d 3-5 days, followed by 250 mg/d 3-5</td></t<>   |                                     |                          | multivitamin supplements for at-risk patients         | -IV 500 mg/d 3-5 days, followed by 250 mg/d 3-5     |
| Vitamin B12 (cobalamin)       -Post-LSC, post-RYCB,<br>cr post-BPD-DS       -350-500 µg oral/subingual dally<br>to post-BPD-DS       -1,000 µg oral dally<br>to acc acc acc acc acc acc acc acc acc ac  |                                     |                          |   | days or until symptoms resolve, then 100 mg/d       |
| Vtamin B12 (cobalamin)       -bost-LSG, post-RYGB, or 2500 ug oral/subingual daily       -1,000 ug daily to ach         Folate       -All patients       -1,000 ug oral daily       resume recommender         Folate       -All patients       -1,000 ug oral daily       1,000 ug oral daily to ach         Folate       -All patients       -400-800 ug oral daily in women of       -1,000 ug oral daily to males that underwent LAGB, 1,000 ug oral daily to males that underwent LAGB, 1,000 ug oral daily to males that underwent LAGB, 1,000 ug oral daily for males that underwent LAGB, 1,000 ug oral daily for mastruating females that underwent LAGB, 1,000 -1,500 mg oral daily for mastruating females that underwent LAGB, 1,000 -1,500 mg oral daily for mastruating females that underwent LAGB, 1,000 -1,500 mg oral daily for mastruating females that underwent LAGB, 1,000 -1,500 mg oral daily trate 25-OH vitamin D:         Vtamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, 1,000 -2,000 mg/d calcium citrate for patients that underwent LAGB, 1,000 -2,000 mg/d calcium citrate for patients that underwent LAGB, 2,000 -1,000 u/d for patients that underwent LAGB, 2,000  |                                     |                          |   | orally to maintain normal levels                    |
| or post-BPD-D5     -1,000 µg monthly     resume recommender       Folate     -All patients     -400-800 µg oral daily     -1,000 µg oral daily       Folate     -All patients     -600-1,000 µg oral daily     -1,000 µg oral daily       Folat     -All patients     -600-1,000 µg oral daily     -1,000 µg oral daily       Folat     -All patients     -400-800 µg oral daily     -1,000 µg oral daily       Forat     -All patients     -1,000 µg oral daily     -1,000 µg oral daily       Forat     -All patients     -1,000 µg oral daily     -1,000 µg oral daily       For patients     -All patients     -1,000 µg oral daily     -1,000 µg oral daily       For patients     -All patients     -1,000 µg oral daily     -1,000 µg oral daily       For patients     -All patients     -1,000 µg oral daily     -1,000 µg oral daily       For patients     -1,000 µg oral daily     -1,000 µg oral daily     -1,000 µg oral daily       For patients     -1,200-1,500 mg oral daily     -1,200-1,500 mg/d     -1,200-1,500 mg/d       For patients     -1,200-1,500 mg/d     -1,200-1,500 mg/d     -1,200-1,500 mg/d       For patients     -1,200-1,500 mg/d     -1,200-1,500 mg/d     -1,200-1,500 mg/d       For patients     -1,200-1,500 mg/d     -1,200-1,500 mg/d     -1,200-1,500 mg/d       For patient     -1,200-1,500 m  | Vitamin B <sub>12</sub> (cobalamin) | -Post-LSG, post-RYGB,    | -350-500 µg oral/sublingual daily                     | -1,000 µg daily to achieve normal levels and then   |
| Foldet       -All patients       -400-900 go ral daily in women of the the the the the doages of a single to the the the the doages of a single to the the the the doages of a single to the the the the the the the the the the  |                                     | or post-BPD-DS           | -1,000 µg IM monthly                                  | resume recommended dosages to maintain normal       |
| Folde     -All patients     -400-800 µg oral daily     -1.000 µg oral daily to mene of       Folde     -900-1,000 µg oral daily for meles that underwent LAGB,     -1.000 µg oral daily for meles that underwent LAGB,       Fron     -All patients     -1.8 mg oral daily for meles that underwent LAGB,     -1.500 mg oral daily for meles that underwent LAGB,       Iron     -All patients     -1.8 mg oral daily for meles that underwent LAGB,     -1.500 mg oral daily for mestruating females that       Vitamin D and calcium     -All patients     -1.400-1,500 mg/d calcium citrate for patients that underwent LAGB,     -1.200-1,500 mg/d calcium citrate for patients that underwent LAGB,       Vitamin D and calcium     -All patients     -1.200-1,500 mg/d calcium citrate for patients that underwent LAGB,     -1.200-1,500 mg/d calcium citrate for patients that underwent LAGB,       Vitamin A     -Post-RPD-DS,     -5.000 U/d for patients that underwent LAGG     -1.000-1,500 mg/d calcium citrate for patients that underwent LAGB,       Vitamin A     -Post-RYGB with protein-     -5.000 U/d for patients that underwent LAGG     -1.000-25,000 U/d calcium citrate       Vitamin A     -5.000 U/d for patients that underwent BPD-DS,     -5.000 U/d for patients that underwent LAGG     -1.000-25,000 U/d calcium citrate       Vitamin A     -600-10.000 U/d for patients that underwent BPD-DS     -1.000-25,000 U/d calcium citrate     -1.000-25,000 U/d calcium citrate       Vitamin E     -5000 U/d for patients that underwent LAGG     -5000 U  |                                     |                          |   | levels  |
| Icon       -000 ug oral daily in women of       then resume dosages         Icon       -All patients       -18 mg oral daily for males that underwent LAGB,       -150-200 mg orall daily for males that underwent LAGB,       -150-200 mg orall daily for males that underwent LAGB,       -150-200 mg orall daily for males that underwent LAGB,       -150-200 mg orall daily for males that       -120-1,500 mg/d acilium citrate for patients that underwent LAGB,       -1,200-1,500 mg/d acilium citrate for patients that underwent LAGB,         Vitamin D and calcium       -All patients       -All patients       -1,200-1,500 mg/d acilium citrate for patients that underwent LAGB,       -1,200-1,500 mg/d acilium citrate for patients that underwent LAGB,       -1,200-1,500 mg/d acilium citrate for patients that underwent LAGB,       -1,200-1,500 mg/d acilium citrate for patients that underwent LAGB,       -1,200-5,000 utamin D;         Vtamin A       -Post-BPD-DS,       -2,000 Ut/d for patients that underwent LABG       -1,000-6,000 ut/d racium citrate for patients that underwent LABG       -5,000 Ut/d for patients that underwent LABG       -5,000 Ut/d for patients that underwent LABG       -5,000 Ut/d for patients that underwent LABG       -0,000-6,000 ut/d for patients that underwent that       -3,000-6,000 ut/d racium citrate for patients without         Vtamin A       -Post-BPD-DS,       -S,000 Ut/d for patients that underwent LABG       -1,000-6,000 ut/d for patients that underwent LABG       -10,000-6,000 ut/d for patients that underwent LABG       -10,000-5,000 Ut/d for patients that underwent LABG       -10,000 -5  | Folate                              | -All patients            | -400-800 µg oral daily                                | -1,000 µg oral daily to achieve normal levels and   |
| Iron     -All patients     childbæring age     ormal sets       Iron     -All patients     -18 mg oral daily for males that underwent LAGB,     150-200 mg oral y daily for males that       Iron     -All patients     -18 mg oral daily for manstruating females that     orally 2-3 times daily       Iron     -All patients     -45-60 mg oral daily for manstruating females that     orally 2-3 times daily       Iron     -All patients     -1,000-1,500 mg/d calcium citrate for patients that underwent LAGB,     orally 2-3 times daily       Iron     -All patients     -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB,     -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB,       Iron     -All patients     -1,200-1,500 mg/d calcium citrate for patients that underwent BPD-DS     -3,000-6,000 vitamin D:       Iron     -1,000 -1,000 U/d for patients that underwent BPD-DS     -3,000-6,000 vitamin D:     -3,000-6,000 vitamin D:       Iron     -10,000 U/d for patients that underwent BPD-DS     -3,000-6,000 Vitamin D:     -3,000-6,000 Vitamin D:       Iron     -10,000 U/d for patients that underwent BPD-DS     -5,000 U/d for patients that underwent BPD-DS     -5,000 U/d for patients that underwent BPD-DS       Iron     -5,000 U/d for patients that underwent BPD-DS     -10,000 U/d for patients that underwent BPD-DS     -5,000 U/d for patients that underwent BPD-DS       Iron     -5,000 U/d for patients that underwent BPD-DS     -10,000   |                                     |                          | -800-1,000 µg oral daily in women of                  | then resume dosages recommended to maintain         |
| Iron     -All patients     -18 mg oral daily for males that underwert LAGB,     -150-200 mg orally di       LSG, or RYBG     LSG, or RYBG     -Dose should be increase incr                          |                                     |                          | childbearing age                                      | normal levels                                       |
| LSG, or RYBG       -Dose should be increased and y for menstruating females that       -Dose should be increased and y underwent LAGB, LSG, or RYBG       -Foose should be increased and y underwent LAGB, LSG, or RYBG       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -3,000 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       -3,000 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,500 UJ/d       -3,000 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,600-2,500 UJ/d       -5,000 UJ/d for patients that underwent LAGB, LSG, or RYBG; 1,600-2,500 UJ/d       -5,000 UJ/d for patients that underwent BPD-DS, IU/d IN RO 2, 4,000       -3,000 mg/d       -5,000 UJ/d       -5,000 UJ/d for patients that underwent BPD-DS, IU/d IN RO 2, 4,000       -5,000 UJ/d for patients that underwent BPD-DS, IU/d IN RO 2, 4,000       -5,000 UJ/d for patients that underwent  | Iron                                | -All patients            | -18 mg oral daily for males that underwent LAGB,      | -150-200 mg orally daily                            |
| -45-60 mg oral daily for menstruating females that       orally 2-3 times daily         Vitamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, Cs or RYBG; 1,800-2,400 mg/d         Vitamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, calcium citrate for patients that underwent LAGB, calcium citrate for patients that underwent LAGB, calcium citrate for patients that underwent LAGB, calcium citrate for patients that underwent LAGB, calcium citrate for patients without.         Vitamin A       -Post-BPD-DS, -5,000 IU/d for patients that underwent LABG       -5,000 IU/d for patients that underwent LABG         Vitamin A       -Post-RYGB with protein-       -5,000-10,000 IU/d for patients that underwent BPD-DS       -10,000 25,000 IU/d cr         Vitamin B       -5,000-10,000 IU/d for patients that underwent BPD-DS       -10,000 25,000 IU/d cr       -60 patients with cor         Vitamin B       -Symptomatic patients       -5,000-10,000 IU/d for patients that underwent BPD-DS       10,000-25,000 IU/d cr         Vitamin B       -Symptomatic patients       -5,000 IU/d for patients that underwent BPD-DS       10,000-25,000 IU/d cr         Vitamin E       -Symptomatic patients       -5,000 IU/d for patients that underwent BPD-DS       10,000-25,000 IU/d cr         Vitamin E       -Symptomatic patients       -5,000 IU/d for patients that underwent BPD-DS  |                                     |                          | LSG, or RYBG  | -Dose should be increased as high as 300 mg         |
| Vitamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that         Vitamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       +hat underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d         Vitamin D       -All patients       -1,200-1,500 mg/d calcium citrate for patients that underwent BPD-DS       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, calcium citrate for patients that underwent LAGB, calcium citrate for patients         Vitamin A       -Post-BPD-DS,       -5,000 U/d for patients that underwent LABG       -5,000 U/d for patients that underwent LABG         Vitamin A       -Post-RYGB with protein-       -5,000 U/d for patients that underwent LABG       -5,000 U/d for patients that underwent LABG       -5,000 U/d for patients that underwent LABG         Vitamin B       -Post-RYGB with protein-       -10,000 U/d for patients that underwent BPD-DS       -5,000 U/d for patients that underwent BPD-DS       -5,000 U/d for patients that underwent BPD-DS         Vitamin E       -Symptomatic       -5,000 U/d for patients that underwent BPD-DS       -5,000 U/d for patients that underwent BPD-DS       -5,000 U/d for patients that underwent BPD-DS         Vitamin E       -Symptomatic       -5,000 U/d for patients that underwent BPD-DS       -5,000 Vitamin C       -5,000 Vitamin C         Vitamin E       -Symptomatic </td <td></td> <td></td> <td>-45-60 mg oral daily for menstruating females that</td> <td>orally 2-3 times daily</td>   |                                     |                          | -45-60 mg oral daily for menstruating females that    | orally 2-3 times daily                              |
| Vitamin D and calcium       -All patients       -1,200-1,500 mg/d calcium citrate for patients that       -1,200-1,500 mg/d calcium citrate for patients that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       that underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d         Regular Citrate for patients that underwent BPD-DS       aclium citrate for patients that underwent BPD-DS       mg/d calcium citrate for patients that underwent LAGB, CSG, or NTAMIN       -3,000-6,000 vitamin D         Revel to 30 ng/mL       -3,000 vitamin D3 U daily, titrate 25-OH vitamin D       -3,000-6,000 vitamin D       -3,000-6,000 vitamin D         Vitamin A       -Post-BPD-DS,       -5,000 U/d for patients that underwent LABG       For patients without:         Vitamin A       -Post-BPD-DS,       -5,000 U/d for patients that underwent LABG       For patients without:         Vitamin A       -Post-RVGB with protein-       -1,0000 U/d for patients that underwent LABG       10,000-25,000 U/d for 2 d, follow         Post-RVGB with protein-       -10,000 U/d for patients that underwent BPD-DS       10,000-25,000 U/d for patients with cor         Post-RVGB with protein-       -10,000 U/d for patients that underwent BPD-DS       10,000-25,000 U/d for patients that underwent BPD-DS         Vitamin E       -Symptomatic       -10,000 U/d for patients that underwent BPD-DS       10,000-25,000 U/d for patients that underwent BPD-DS         Vitamin E       -Symptomatic       -10,000 U/d for patients that underwent BPD-DS       10/d  |                                     |                          | underwent LAGB, LSG, or RYBG                          |   |
| Underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d       that underwent LAGB, active of that underwent LAGB, active of trate for patients that underwent BPD-DS       -3,000 vitamin D3 10 daily, titrate 25-OH vitamin D       -3,000-6,000 vitamin D         -3,000 vitamin D3       -9,000 vitamin D3       -3,000 vitamin D3       -3,000 vitamin D3         Vitamin A       -Post-BPD-DS,       -5,000 10/d for patients that underwent LABG       -5,000 10/d for patients that underwent LABG       -5,000 10/d for patients that underwent LABG         Vitamin A       -Post-BPD-DS,       -5,000 10/d for patients that underwent LABG       -60 patients without.         -Post-RYGB with protein-       underwent RYGB or LSG       -for patients with correcter improvement         -Post-RYGB with protein-       underwent BPD-DS       10,000-25,000 10/d for patients that underwent BPD-DS       10/d IM for 3 d, follow         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -60 patients with correcter improvement         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -15 mg/d       -60 patients with correcter improvement         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -60 patients with correcter improvement         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -60 patients with correcter improvement         Vitamin E       -   | Vitamin D and calcium               | -All patients            | -1,200-1,500 mg/d calcium citrate for patients that   | -1,200-1,500 mg/d calcium citrate for patients      |
| calcium citrate for patients that underwent BPD-DS       -3,000 vitamin D3 IU daily, titrate 25-OH vitamin D       BPD-DS         -3,000 vitamin       -3,000 vitamin D3 IU daily, titrate 25-OH vitamin D       -3,000-6,000 vitamin D3         Vitamin A       -Post-BPD-DS,       -5,000 IU/d for patients that underwent LABG       -5,000 IU vitamin D1         Vitamin A       -Post-BPD-DS,       -5,000 IU/d for patients that underwent LABG       -6r patients without -         regardless of symptoms       -5,000 IU/d for patients that underwent LABG       10,000-25,000 IU/d or         Post-RYGB with protein-       -nuderwent RYGB or LSG       -for patients with cor         regardless of symptoms       -10,000 IU/d for patients that underwent BPD-DS       -for patients with cor         Vitamin E       -Symptomer       -10,000 IU/d for patients that underwent BPD-DS       -for patients with cor         Vitamin E       -Symptomatic       -15 mg/d       -15 mg/d       -for patients with cor         Vitamin E       -Symptomatic       -15 mg/d       -15 mg/d       -15 mg/d       -0ptimal dose for patients of 100-4         Vitamin E       -Symptomatic       -15 mg/d       -15 mg/d       -15 mg/d       -10 patients of 100-4         Poster       -Symptomatic       -15 mg/d       -15 mg/d       -15 mg/d       -10 patients of 100-4       -10 patients of 100-4   |                                     |                          | underwent LAGB, LSG, or RYBG; 1,800-2,400 mg/d        | that underwent LAGB, LSG, or RYBG, 1,800-2,400      |
| -3,000 vitamin D3 IU daily, titrate 25-OH vitamin D       BPD-DS         Ievel to 30 ng/mL       -3,000-6,000 vitamin D:         -5,000 IU vitamin D:       -5,000 IU/d for patients that underwent LABG       -5,000 IU/d of patients that underwent LABG         Vitamin A       -Post-BPD-DS,       -5,000 IU/d for patients that underwent LABG       -For patients without.         Vitamin A       -Post-RYGB with protein-       -5,000 IU/d for patients that underwent LABG       -For patients without.         Post-RYGB with protein-       underwent RYGB or LSG       -For patients with cor       10,000-25,000 IU/d of patients that underwent BPD-DS       -For patients with cor         Vitamin E       -Symptomatic patients       -10,000 IU/d for patients that underwent BPD-DS       -For patients with cor         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -optimal dose for patients of 100-4         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -10 patients of 100-4         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -0ptimal dose for patients of 100-4   |                                     |                          | calcium citrate for patients that underwent BPD-DS    | mg/d calcium citrate for patients that underwent    |
| Ievel to 30 ng/mL       -3,000-6,000 vitamin         Vitamin A       -Post-BPD-DS,       -5,000 U/d for patients that underwent LABG       -For patients without         Vitamin A       -Post-BPD-DS,       -5,000-10,000 U/d for patients that       -10,000-25,000 U/d of         Vitamin A       regardless of symptoms       -5,000-10,000 U/d for patients that       10,000-25,000 U/d of         Post-RYGB with protein-       underwent RYGB or LSG       10,000-25,000 U/d of       10,000-25,000 U/d of         Post-RYGB with protein-       underwent RYGB or LSG       10,000-25,000 U/d of       10,000-25,000 U/d of         Calorie malnutrition       -10,000 U/d for patients that underwent BPD-DS       10,000-25,000 U/d of       10,000-25,000 U/d of         Vitamin E       -Symptomatic       -10,000 U/d for patients that underwent BPD-DS       10/d IM for 3 d, follow         Kitamin E       -Symptomatic patients       -15 mg/d       60r two weeks       60r two weeks         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -0ptimal dose for patients is not defined         Antioxidant benefits       -Symptomatic patients       -15 mg/d       -15 mg/d       -0ptimal dose for patients is not defined  |                                     |                          | -3,000 vitamin D3 IU daily, titrate 25-OH vitamin D   | BPD-DS  |
| -Formula D2       -50,000 IU vitamin D2         -Formula D2       -50,000 IU/d for patients that underwent LABG       -For patients without of the patients that underwent LABG         Vitamin A       -Post-BPD-DS,       -5,000-10,000 IU/d for patients that       10,000-25,000 IU/d of patients without of improvement         Post-RYGB with protein-       underwent RYGB or LSG       10,000-25,000 IU/d of patients that underwent BPD-DS       10,000-25,000 IU/d of patients that underwent BPD-DS         Vitamin E       -Symptomatic patients       -10,000 IU/d for patients that underwent BPD-DS       -for patients with corr         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -optimal dose for patients for 100-4         Vitamin E       -Symptomatic patients       -15 mg/d       -15 mg/d       -10 optimal dose for patients for 100-4   |                                     |                          | level to 30 ng/mL                                     | -3,000-6,000 vitamin D3 IU/d                        |
| Vitamin A       -Post-BPD-DS,       -5,000 IU/d for patients that underwent LABG       -For patients without a regardless of symptoms       -5,000-10,000 IU/d for patients that       10,000-25,000 IU/d o improvement         Post-RYGB with protein-       underwent RYGB or LSG       10,000-25,000 IU/d o improvement       10,000-25,000 IU/d o improvement         Post-RYGB with protein-       underwent RYGB or LSG       improvement       10,000-25,000 IU/d o improvement         Post-RYGB with protein-       underwent RYGB or LSG       improvement       -For patients with con         IU/d IM for 3 d, follow       -10,000 IU/d for patients that underwent BPD-DS       IU/d IM for 3 d, follow         Kortwo weeks       Nitamin E       -Symptomatic patients       -For patients with con         Vitamin E       -Symptomatic patients       -15 mg/d       surgery is not defined         Antioxidant benefits       -Symptomatic patients       -15 mg/d       surgery is not defined         Optimal dose for patients       -15 mg/d       -15 mg/d       surgery is not defined         Optimal dose for patients       -15 mg/d       -15 mg/d       surgery is not defined         -Antioxidant benefits       -50 molecular       -15 mg/d       surgery is not defined  |                                     |                          |   | -50,000 IU vitamin D2 IU/weekly                     |
| regardless of symptoms       -5,000-10,000 IU/d for patients that       10,000-25,000 IU/d of         Post-RYGB with protein-       underwent RYGB or LSG       improvement         -Post-RYGB with protein-       underwent RYGB or LSG       improvement         -Post-RYGB with protein-       10,000 IU/d for patients that underwent BPD-DS       10,000-25,000 IU/d for patients that underwent BPD-DS         IU/d IM for 3 d, follow       10,000 IU/d for patients that underwent BPD-DS       For patients with corn         Nitamin E       -Symptomatic patients       -15 mg/d       for two weeks         Vitamin E       -Symptomatic patients       -15 mg/d       surgery is not defined         -Antioxidant benefits       surgery is not defined       -Antioxidant benefits  | Vitamin A                           | -Post-BPD-DS,            | -5,000 IU/d for patients that underwent LABG          | -For patients without corneal changes,              |
| -Post-RYGB with protein-       underwent RYGB or LSG       improvement         calorie malnutrition       -10,000 IU/d for patients that underwent BPD-DS       -For patients with corr         IU/d IM for 3 d, follow       for two weeks       for two weeks         Vitamin E       -Symptomatic patients       -15 mg/d       -Optimal dose for patients         Vitamin E       -Symptomatic patients       -15 mg/d       surgery is not defined         -Antioxidant benefits       -Supplements of 100-4       -Antioxidant benefits   |                                     | regardless of symptoms   | -5,000-10,000 IU/d for patients that                  | 10,000-25,000 IU/d orally until clinical symptoms   |
| Calorie malnutrition     -10,000 IU/d for patients that underwent BPD-DS     -For patients with corr       IU/d IM for 3 d, follow     for two weeks     for two weeks       Vitamin E     -Symptomatic patients     -15 mg/d     coptimal dose for patient       surgery is not defined     -Antioxidant benefits     100-4  |                                     | -Post-RYGB with protein- | underwent RYGB or LSG                                 | improvement   |
| IU/d IM for 3 d, follow<br>for two weeks<br>Vitamin E -Symptomatic patients -15 mg/d -Optimal dose for pati<br>surgery is not defined<br>-Antioxidant benefits<br>supplements of 100-4  |                                     | calorie malnutrition     | -10,000 IU/d for patients that underwent BPD-DS       | -For patients with corneal changes 50,000-100,000   |
| for two weeks Vitamin E -Symptomatic patients -15 mg/d -Optimal dose for pati surgery is not defined -Antioxidant benefits supplements of 100-4   |                                     |                          |   | IU/d IM for 3 d, followed by 50,000 IU/d IM         |
| Vitamin E   |                                     |                          |   | for two weeks                                       |
| surgery is not defined<br>-Antioxidant benefits<br>supplements of 100-4   | Vitamin E                           | -Symptomatic patients    | -15 mg/d  | -Optimal dose for patients that underwent bariatric |
| -Antioxidant benefits a supplements of 100-4  |                                     |                          |   | surgery is not defined                              |
| supplements of 100-4  |                                     |                          |   | -Antioxidant benefits can be achieved with          |
|   |                                     |                          |   | supplements of 100-400 IU/d Continue→               |

was 5-10 times greater (79). An increased risk of fracture after LSG remains inconclusive. Old age is also an important factor that can increase the risk of fractures (80).

Dual-energy X-ray absorptiometry can be inaccurate in patients with obesity, especially during the process of weight loss. In patients who have undergone malabsorptive surgery, bone mineral density measurements may be recommended at baseline after two years (2). Antiresorptive agents may be prescribed to patients with osteoporosis after bariatric surgery after the patient has received adequate treatment for calcium and vitamin D deficiencies. Antiresorptive agents (bisphosphonates or denosumab) should be administered intravenously or subcutaneously to avoid the risks of anastomotic ulceration and reflux that can occur if bisphosphonates are given orally (2).

#### **Foul-Smelling Diarrhea**

Foul-smelling diarrhea arises due to the malabsorption of protein, fat, calcium, iron, and vitamin  $B_{12}$ .

## Kwashiorkor

a paroscopic adjustable gastric banding (LAGB); Laparoscopic sleeve gastrectomy (LSG); Roux-en-Y gastric bypass (RYGB); Biliopancreatic diversion with duodenal switch (BPD-DS); Day

(d); Intravenous (IV); Intramuscular (IM), International Unit (IU)

Kwashiorkor is a potentially lethal form of protein malnutrition.

# **Unwillingness to Eat**

Unwillingness to eat is observed during the transition of diets from fluid food to soft food and then to normal food. Patients can be angry and disappointed because their food volume is reduced after bariatric surgery compared with the preoperative period. Therefore, patients should be persuaded to eat. Most patients can tolerate normal food by the 6<sup>th</sup> month of the postoperative period. If emesis continues, the presence of ulcers or any gastric obstruction should be detected (2).

## **Food Intolerance**

Food intolerance is seen especially toward red meat. Patients may prefer a vegetarian diet (2).

## **Dumping Syndrome**

Dumping syndrome is most commonly reported after procedures that do not keep the pylorus intact. Early dumping occurs commonly within one hour of RYBG, after eating mainly refined carbohydrate or fatty food. It is due to the passage of hyperosmolar gastric

|               | יוור מפווכופווכופא' וומתופוור אחלאופווופון | ונמנוטוו, מווט רפטיפוואוווופות מונפו שפוטות וטאא אטוטפוץ (ב, | o) (continue).                                       |
|---------------|--|--|--|
| Micronutrient | Monitoring                                 | Supplementation to prevent deficiency                        | Replenishment for patients with deficiency           |
| Vitamin K     | -Symptomatic patients                      | -90-120 µg/d for patients that underwent                     | -10 mg parenterally for patients with acute          |
|               |  | LAGB, LSG, o RYGB  | -Either 1-2 mg/d orally or 1-2 mg/week parenterally  |
|               |  | -300 µg/d for patients that underwent BPD-DS                 | for patients with chronic malabsorption              |
| Zinc          | -Post-RYGB, post-BPD-DS annually           | -8-11 mg/d for patients that underwent LAGB or LSG           | -Sufficient data is unavailable                      |
|               | -Anemia without iron deficiency            | -8-22 mg/d for patients that underwent RYGB                  | -Screened routinely and avoid copper deficiency      |
|               |  | -BPD-DS: 16-22 mg/d for patients that underwent BPD-DS       |  |
| Copper        | -Post-RYGB, post-BPD-DS annually           | -1 mg/d for patients that underwent LAGB and LSG             | -3-8 mg/d orally for mild to moderate deficiency,    |
|               |  | -2 mg/d for patients that underwent RYGB or BPD-DS           | 2-4 mg/d IV for severe deficiency until serum levels |
|               |  |  | return to normal                                     |
|               |  |  |  |

content in the jejunum, with shifts in intravascular fluid in the intestinal lumen. Abdominal pain, nausea, fatigue, diarrhea, and tachycardia may also be observed (81). Late dumping occurs 1-4 h after eating high

glycemic index foods. Postprandial reactive hypoglycemia occurs in response to hyperinsulinemia. Symptoms such as nausea, sweating, tremor, palpitation, altered consciousness, and syncope can be observed (81).

## Hypervitaminosis

Previous studies have reported hypervitaminosis in patients due to excess intake of vitamins. The excessive levels of vitamin B1, B6, B12, and folate were identified (82,83). Vitamin B6 toxicity was associated with the development of sensory neuropathy (84).

## Conclusion

Nutrition after bariatric surgery is divided into five stages that start after the surgery and continue until the patient resumes a normal diet. Vitamins and minerals that the patient is unable to receive from the regular diet are provided as supplements. The amount of supplements prescribed differs based on the procedure. The most important complication that can occur after bariatric surgery is nutritional deficiencies. The quantity of vitamins and minerals needed by the patient should be determined preoperatively. Deficient vitamins and minerals should be prescribed preoperatively. Routine screening for vitamins and minerals should be performed postoperatively. If any deficiency is detected, the appropriate vitamins and minerals should be prescribed accordingly.

# **Source of Finance**

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

# **Conflict of Interest**

No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

# **Authorship Contributions**

Idea/Concept: Havva Sezer, Dilek Yazıcı; Design: Havva Sezer, Dilek Yazıcı; Control/Supervision: Havva Sezer, Dilek Yazıcı; Data Collection and/or Processing: Havva Sezer, Dilek Yazıcı; Analysis and/or Interpretation: Havva Sezer, Dilek Yazıcı; Literature Review: Havva Sezer, Dilek Yazıcı; Writing the Article: Havva Sezer, Dilek Yazıcı; Critical Review: Dilek Yazıcı.

## References

- Deveney CW, Martindale RG. Factors in selecting the optimal bariatric procedure for a specific patient and parameters by which to measure appropriate response to surgery. Curr Gastroenterol Rep. 2010;12:296-303. [Crossref] [PubMed]
- Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21 Suppl 1:S1-27. [Crossref] [PubMed] [PMC]
- Gehrer S, Kern B, Peters T, Christoffel-Courtin C, Peterli R. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study. Obes Surg. 2010;20:447-453. [Crossref] [PubMed]4. Coupaye M, Puchaux K, Bogard C, Msika S, Jouet P, Clerici C, Larger E, Ledoux S. Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study. Obes Surg. 2009;19:56-65. [Crossref] [PubMed]
- 5. Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Fi-garo MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16:175-247. [Crossref] [PubMed]
- Chowbey PK, Dhawan K, Khullar R, Sharma A, Soni V, Baijal M, Mittal T. Laparoscopic sleeve gastrectomy: an Indian experience-surgical technique and early results. Obes Surg. 2010;20:1340-1347. [Crossref] [PubMed]

- Behrens C, Tang BQ, Amson BJ. Early results of a Canadian laparoscopic sleeve gastrectomy experience. Can J Surg. 2011;54:138-143. [Crossref] [PubMed] [PMC]
- Heusschen L, Schijns W, Ploeger N, Deden LN, Hazebroek EJ, Berends FJ, Aarts EO. The True Story on Deficiencies After Sleeve Gastrectomy: Results of a Double-Blind RCT. Obes Surg. 2020;30:1280-1290. [Crossref] [PubMed]
- Kondrup J, Allison SP, Elia M, Vellas B, Plauth M; Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN). ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22:415-421. [Crossref] [PubMed]
- Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-454. [PubMed] [PMC]
- Nguyen NT, Silver M, Robinson M, Needleman B, Hartley G, Cooney R, Catalano R, Dostal J, Sama D, Blankenship J, Burg K, Stemmer E, Wilson SE. Result of a national audit of bariatric surgery performed at academic centers: a 2004 University HealthSystem Consortium Benchmarking Project. Arch Surg. 2006;141:445-449; discussion 449-450. [Crossref] [PubMed]
- DeMaria EJ, Sugerman HJ, Kellum JM, Meador JG, Wolfe LG. Results of 281 consecutive total laparoscopic Rouxen-Y gastric bypasses to treat morbid obesity. Ann Surg. 2002;235:640-645; discussion 645-647. [Crossref] [PubMed] [PMC]
- Marshall JS, Srivastava A, Gupta SK, Rossi TR, DeBord JR. Roux-en-Y gastric bypass leak complications. Arch Surg. 2003;138:520-3; discussion 523-524. [Crossref] [PubMed]
- 14. Gonzalez R, Sarr MG, Smith CD, Baghai M, Kendrick M, Szomstein S, Rosenthal R, Murr MM. Diagnosis and contemporary management of anastomotic leaks after gastric bypass for obesity. J Am Coll Surg. 2007;204:47-55. [Crossref] [PubMed]
- Fried M, Ribaric G, Buchwald JN, Svacina S, Dolezalova K, Scopinaro N. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010;20:776-790. [Crossref] [PubMed]
- Breznikar B, Dinevski D. Bariatric surgery for morbid obesity: pre-operative assessment, surgical techniques and post-operative monitoring. J Int Med Res. 2009;37:1632-1645. [Crossref] [PubMed]
- Bloomberg RD, Fleishman A, Nalle JE, Herron DM, Kini S. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145-154. [Crossref] [PubMed]
- Topart P, Becouarn G, Sallé A, Ritz P. Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis. 2014;10:936-941. [Crossref] [PubMed]
- Dalcanale L, Oliveira CP, Faintuch J, Nogueira MA, Rondó P, Lima VM, Mendonça S, Pajecki D, Mancini M, Carrilho FJ. Long-term nutritional outcome after gastric bypass. Obes Surg. 2010;20:181-187. [Crossref] [PubMed]

- Gong K, Gagner M, Pomp A, Almahmeed T, Bardaro SJ. Micronutrient deficiencies after laparoscopic gastric bypass: recommendations. Obes Surg. 2008;18:1062-1066. [Crossref] [PubMed]
- Tucker ON, Szomstein S, Rosenthal RJ. Nutritional consequences of weight-loss surgery. Med Clin North Am. 2007;91:499-514, xii. [Crossref] [PubMed]
- 22. Guan B, Yang J, Chen Y, Yang W, Wang C. Nutritional Deficiencies in Chinese Patients Undergoing Gastric Bypass and Sleeve Gastrectomy: Prevalence and Predictors. Obes Surg. 2018;28:2727-2736. [Crossref] [PubMed]
- Ledoux S, Msika S, Moussa F, Larger E, Boudou P, Salomon L, Roy C, Clerici C. Comparison of nutritional consequences of conventional therapy of obesity, adjustable gastric banding, and gastric bypass. Obes Surg. 2006;16:1041-1049. [Crossref] [PubMed]
- 24. Steenackers N, Van der Schueren B, Mertens A, Lannoo M, Grauwet T, Augustijns P, Matthys C. Iron deficiency after bariatric surgery: what is the real problem? Proc Nutr Soc. 2018;77:445-455. [Crossref] [PubMed]
- Sabate JM, Coupaye M, Ledoux S, Castel B, Msika S, Coffin B, Jouet P. Consequences of Small Intestinal Bacterial Overgrowth in Obese Patients Before and After Bariatric Surgery. Obes Surg. 2017;27:599-605. [Crossref] [PubMed]
- Ponsky TA, Brody F, Pucci E. Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass. J Am Coll Surg. 2005;201:125-131. [Crossref] [PubMed]
- Bellanger DE, Greenway FL. Laparoscopic sleeve gastrectomy, 529 cases without a leak: short-term results and technical considerations. Obes Surg. 2011;21:146-150. [Crossref] [PubMed]
- Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37:S66-70. [Crossref] [PubMed]
- Verger EO, Aron-Wisnewsky J, Dao MC, Kayser BD, Oppert JM, Bouillot JL, Torcivia A, Clément K. Micronutrient and Protein Deficiencies After Gastric Bypass and Sleeve Gastrectomy: a 1-year Follow-up. Obes Surg. 2016;26:785-796. [Crossref] [PubMed]
- Aron-Wisnewsky J, Verger EO, Bounaix C, Dao MC, Oppert JM, Bouillot JL, Chevallier JM, Clément K. Nutritional and Protein Deficiencies in the Short Term following Both Gastric Bypass and Gastric Banding. PLoS One. 2016;11:e0149588. [Crossref] [PubMed] [PMC]
- 31. Giusti V, Theytaz F, Di Vetta V, Clarisse M, Suter M, Tappy L. Energy and macronutrient intake after gastric bypass for morbid obesity: a 3-y observational study focused on protein consumption. Am J Clin Nutr. 2016;103:18-24. [Crossref] [PubMed]
- 32. Schollenberger AE, Karschin J, Meile T, Küper MA, Königsrainer A, Bischoff SC. Impact of protein supplementation after bariatric surgery: A randomized controlled double-blind pilot study. Nutrition. 2016;32:186-192. [Crossref] [PubMed]
- 33. Lopes Gomes D, Moehlecke M, Lopes da Silva FB, Dutra ES, D'Agord Schaan B, Baiocchi de Carvalho KM. Whey Protein Supplementation Enhances Body Fat and Weight Loss in Women Long After Bariatric Surgery: a Randomized Controlled Trial. Obes Surg. 2017;27:424-431. [Crossref] [PubMed]

- 34. Johnson JM, Maher JW, DeMaria EJ, Downs RW, Wolfe LG, Kellum JM. The long-term effects of gastric bypass on vitamin D metabolism. Ann Surg. 2006;243:701-704; discussion 704-705. [Crossref] [PubMed] [PMC]
- 35. Clements RH, Katasani VG, Palepu R, Leeth RR, Leath TD, Roy BP, Vickers SM. Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am Surg. 2006;72:1196-1202; discussion 1203-1204. [Crossref] [PubMed]
- 36. Coates PS, Fernstrom JD, Fernstrom MH, Schauer PR, Greenspan SL. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061-1065. [Crossref] [PubMed]
- 37. Youssef Y, Richards WO, Sekhar N, Kaiser J, Spagnoli A, Abumrad N, Torquati A. Risk of secondary hyperparathyroidism after laparoscopic gastric bypass surgery in obese women. Surg Endosc. 2007;21:1393-1396. [Crossref] [PubMed]
- Aigner E, Feldman A, Datz C. Obesity as an emerging risk factor for iron deficiency. Nutrients. 2014;6:3587-3600. [Crossref] [PubMed] [PMC]
- Han O. Molecular mechanism of intestinal iron absorption. Metallomics. 2011;3:103-109. [Crossref] [PubMed]
- 40. Mu-oz M, Botella-Romero F, Gómez-Ramírez S, Campos A, García-Erce JA. Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management. Nutr Hosp. 2009;24:640-654. [PubMed]
- 41. Ben-Porat T, Elazary R, Yuval JB, Wieder A, Khalaileh A, Weiss R. Nutritional deficiencies after sleeve gastrectomy: can they be predicted preoperatively? Surg Obes Relat Dis. 2015;11:1029-1036. [Crossref] [PubMed]
- 42. Ledoux S, Flamant M, Calabrese D, Bogard C, Sami O, Coupaye M. What Are the Micronutrient Deficiencies Responsible for the Most Common Nutritional Symptoms After Bariatric Surgery? Obes Surg. 2020;30:1891-1897. [Crossref] [PubMed]
- 43. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13:727-741. [Crossref] [PubMed]
- 44. Lakdawala MA, Bhasker A, Mulchandani D, Goel S, Jain S. Comparison between the results of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass in the Indian population: a retrospective 1 year study. Obes Surg. 2010;20:1-6. [Crossref] [PubMed]
- 45. Abbatini F, Rizzello M, Casella G, Alessandri G, Capoccia D, Leonetti F, Basso N. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24:1005-1010. [Crossref] [PubMed]
- 46. Al-Mutawa A, Al-Sabah S, Anderson AK, Al-Mutawa M. Evaluation of Nutritional Status Post Laparoscopic Sleeve Gastrectomy-5-Year Outcomes. Obes Surg. 2018;28:1473-1483. [Crossref] [PubMed]
- 47. Marcuard SP, Sinar DR, Swanson MS, Silverman JF, Levine JS. Absence of luminal intrinsic factor after gastric bypass surgery for morbid obesity. Dig Dis Sci. 1989;34:1238-1242. [Crossref] [PubMed]

- Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006;91:4223-4231. [Crossref] [PubMed]
- 49. Long AN, Atwell CL, Yoo W, Solomon SS. Vitamin B(12) deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care. 2012;35:e84. [Crossref] [PubMed] [PMC]
- Brolin RE, LaMarca LB, Kenler HA, Cody RP. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg. 2002;6:195-203; discussion 204-5. [Crossref] [PubMed]
- Skroubis G, Sakellaropoulos G, Pouggouras K, Mead N, Nikiforidis G, Kalfarentzos F. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg. 2002;12:551-558. [Crossref] [PubMed]
- 52. Kwon Y, Kim HJ, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. Anemia, iron and vitamin B12 deficiencies after sleeve gastrectomy compared to Roux-en-Y gastric bypass: a meta-analysis. Surg Obes Relat Dis. 2014;10:589-597. [Crossref] [PubMed]
- Capoccia D, Coccia F, Paradiso F, Abbatini F, Casella G, Basso N, Leonetti F. Laparoscopic gastric sleeve and micronutrients supplementation: our experience. J Obes. 2012;2012:672162. [Crossref] [PubMed] [PMC]
- 54. Mallory GN, Macgregor AM. Folate Status Following Gastric Bypass Surgery (The Great Folate Mystery). Obes Surg. 1991;1:69-72. [Crossref] [PubMed]
- Hakeam HA, O'Regan PJ, Salem AM, Bamehriz FY, Eldali AM. Impact of laparoscopic sleeve gastrectomy on iron indices: 1 year follow-up. Obes Surg. 2009;19:1491-1496. [Crossref] [PubMed]
- 56. Saltzman E, Anderson W, Apovian CM, Boulton H, Chamberlain A, Cullum-Dugan D, Cummings S, Hatchigian E, Hodges B, Keroack CR, Pettus M, Thomason P, Veglia L, Young LS. Criteria for patient selection and multidisciplinary evaluation and treatment of the weight loss surgery patient. Obes Res. 2005;13:234-243. [Crossref] [PubMed]
- 57. Liu D, Ke Z, Luo J. Thiamine deficiency and neurodegeneration: the interplay among oxidative stress, endoplasmic reticulum stress, and autophagy. Mol Neurobiol. 2017;54:5440-5448. [Crossref] [PubMed] [PMC]
- Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6:442-455. [Crossref] [PubMed]
- Iannelli A, Addeo P, Novellas S, Gugenheim J. Wernicke's encephalopathy after laparoscopic Roux-en-Y gastric bypass: a misdiagnosed complication. Obes Surg. 2010;20:1594-1596. [Crossref] [PubMed]
- 60. Lakhani SV, Shah HN, Alexander K, Finelli FC, Kirkpatrick JR, Koch TR. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res. 2008;28:293-238. [Crossref] [PubMed]
- Shankar P, Boylan M, Sriram K. Micronutrient deficiencies after bariatric surgery. Nutrition. 2010;26:1031-1037. [Crossref] [PubMed]
- Dolan K, Hatzifotis M, Newbury L, Lowe N, Fielding G. A clinical and nutritional comparison of biliopancreatic diversion with and without duodenal switch. Ann Surg. 2004;240:51-56. [Crossref] [PubMed] [PMC]

424

- Balsa JA, Botella-Carretero JI, Gómez-Martín JM, Peromingo R, Arrieta F, Santiuste C, Zamarrón I, Vázquez C. Copper and zinc serum levels after derivative bariatric surgery: differences between Roux-en-Y Gastric bypass and biliopancreatic diversion. Obes Surg. 2011;21:744-750. [Crossref] [PubMed]
- 64. Livingstone C. Zinc: physiology, deficiency, and parenteral nutrition. Nutr Clin Pract. 2015;30:371-382. [Crossref] [PubMed]
- 65. Wapnir RA. Copper absorption and bioavailability. Am J Clin Nutr. 1998;67:1054S-1060S. [Crossref] [PubMed]
- 66. Griffith DP, Liff DA, Ziegler TR, Esper GJ, Winton EF. Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Obesity (Silver Spring). 2009;17:827-831. [Crossref] [PubMed] [PMC]
- 67. Gletsu-Miller N, Broderius M, Frediani JK, Zhao VM, Griffith DP, Davis SS Jr, Sweeney JF, Lin E, Prohaska JR, Ziegler TR. Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int J Obes (Lond). 2012;36:328-335. [Crossref] [PubMed] [PMC]
- Schweitzer DH, Posthuma EF. Prevention of vitamin and mineral deficiencies after bariatric surgery: evidence and algorithms. Obes Surg. 2008;18:1485-1458. [Crossref] [PubMed]
- 69. Pereira S, Saboya C, Chaves G, Ramalho A. Class III obesity and its relationship with the nutritional status of vitamin A in pre- and postoperative gastric bypass. Obes Surg. 2009;19:738-744. [Crossref] [PubMed]
- 70. Benedix F, Westphal S, Patschke R, Granowski D, Luley C, Lippert H, Wolff S. Weight loss and changes in salivary ghrelin and adiponectin: comparison between sleeve gastrectomy and Roux-en-Y gastric bypass and gastric banding. Obes Surg. 2011;21:616-624. [Crossref] [PubMed]
- 71. Leyba JL, Aulestia SN, Llopis SN. Laparoscopic Rouxen-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. Obes Surg. 2011;21:212-216. [Crossref] [PubMed]
- 72. Omana JJ, Nguyen SQ, Herron D, Kini S. Comparison of comorbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. Surg Endosc. 2010;24: 2513-2517. [Crossref] [PubMed]
- Roizen JD, Long C, Casella A, O'Lear L, Caplan I, Lai M, Sasson I, Singh R, Makowski AJ, Simmons R, Levine MA. Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. J Bone Miner Res. 2019;34:1068-1073. [Crossref] [PubMed] [PMC]

- 74. Cartier A, Lemieux I, Alméras N, Tremblay A, Bergeron J, Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008;93:1931-1938. [Crossref] [PubMed]
- 75. Marcus RL, Addison O, Dibble LE, Foreman KB, Morrell G, Lastayo P. Intramuscular adipose tissue, sarcopenia, and mobility function in older individuals. J Aging Res. 2012;2012:629637. [Crossref] [PubMed] [PMC]
- 76. Stein EM, Carrelli A, Young P, Bucovsky M, Zhang C, Schrope B, Bessler M, Zhou B, Wang J, Guo XE, McMahon DJ, Silverberg SJ. Bariatric surgery results in cortical bone loss. J Clin Endocrinol Metab. 2013;98:541-549. [Crossref] [PubMed] [PMC]
- 77. Scibora LM, Ikramuddin S, Buchwald H, Petit MA. Examining the link between bariatric surgery, bone loss, and osteoporosis: a review of bone density studies. Obes Surg. 2012;22:654-667. [Crossref] [PubMed]
- Crawford MR, Pham N, Khan L, Bena JF, Schauer PR, Kashyap SR. Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery versus medical therapy at 5 years. Endocr Pract. 2018;24: 256-264. [Crossref] [PubMed]
- 79. Nakamura KM, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ 3rd, Kennel KA. Fracture risk following bariatric surgery: a population-based study. Osteoporos Int. 2014;25:151-158. [Crossref] [PubMed] [PMC]
- Javanainen M, Pekkarinen T, Mustonen H, Scheinin T, Leivonen M. Two-year nutrition data in terms of vitamin D, vitamin B12, and albumin after bariatric surgery and long-term fracture data compared with conservatively treated obese patients: a retrospective cohort study. Obes Surg. 2018;28:2968-2975. [Crossref] [PubMed]
- Ramadan M, Loureiro M, Laughlan K, Caiazzo R, Iannelli A, Brunaud L, Czernichow S, Nedelcu M, Nocca D. Risk of dumping syndrome after sleeve gastrectomy and roux-en-y gastric bypass: early results of a multicentre prospective study. Gastroenterol Res Pract. 2016;2016:2570237. [Crossref] [PubMed] [PMC]
- van Rutte PW, Aarts EO, Smulders JF, Nienhuijs SW. Nutrient deficiencies before and after sleeve gastrectomy. Obes Surg. 2014;24:1639-1646. [Crossref] [PubMed]
- Aarts EO, Janssen IM, Berends FJ. The gastric sleeve: losing weight as fast as micronutrients? Obes Surg. 2011;21:207-211. [Crossref] [PubMed] [PMC]
- 84. Alsabah A, Al Sabah S, Al-Sabah S, Al-Serri A, Al Haddad E, Renno WM. Investigating Factors Involved in Post Laparoscopic Sleeve Gastrectomy (LSG) Neuropathy. Obes Surg. 2017;27:1271-1276. [Crossref] [PubMed]